Proton pump inhibitors and risk of vitamin and mineral deficiency: Evidence and clinical implications

Therapeutic Advances in Drug Safety

Volumn 4, Issue 3, 2013, Pages 125-133

  Heidelbaugh, Joel J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

antisecretory therapy; calcium; iron; magnesium; mineral deficiency proton pump inhibitor(s); vitamin B 12; vitamin C; vitamin deficiency

Indexed keywords

ASCORBIC ACID; CALCIUM; CYANOCOBALAMIN; ESOMEPRAZOLE; IRON; MAGNESIUM; MINERAL; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; VITAMIN;

ASCORBIC ACID DEFICIENCY; CALCIUM DEFICIENCY; CYANOCOBALAMIN DEFICIENCY; DRUG MECHANISM; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; MAGNESIUM DEFICIENCY; MAGNESIUM METABOLISM; MINERAL DEFICIENCY; PRIORITY JOURNAL; REVIEW; RISK; VITAMIN DEFICIENCY;

EID: 84880436509     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098613482484     Document Type: Article

References (63)

1. Andres E. Loukili N. Noel E. Kaltenbach G. Ben Abdelgheni M. Perrin A. (2004) vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 171: 251–259.
2. Aseeri M. Schroeder T. Kramer J. Zackula R. (2008) Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium-difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 103: 2308–2313.
3. Bo-Linn G. Davis G. Buddrus D. Morawski S. Santa Ana C. Fordtran J. (1984) An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 73: 640–647.
4. Cundy T. Mackay J. (2011) Proton pump inhibitors and severe hypomagnesemia. Curr Opin Gastroenterol 27: 180–185.
5. den Elzen W. Groeneveld Y. de Ruijter W. Souverijn J. le Cessie S. Assendelft W. (2008) Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 27: 491–497.
6. DeVault K. Castell D. (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100: 190–200.
7. Dharmarajan T. Kanagala M. Murakonda P. Lebelt A. Norkus E. (2008) Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc 9: 162–167.
8. Dial S. Delaney J. Barkun A. Suissa S. (2005) Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294: 2989–2995.
9. Drug Topics (2012a) Pharmacy Facts and Figures. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard/drugtopics/252011/727252/article.pdf (accessed 13 October 2012).
10. Drug Topics (2012b) Pharmacy Facts and Figures. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard/drugtopics/252011/727239/article.pdf (accessed 13 October 2012).
11. Farina C. Gagliardi S. (2002) Selective inhibition of osteoclast vacuolar H+-ATPase. Curr Pharm Des 8: 2033–2048.
12. Festen H. (1991) Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl 188: 1–7.
13. Food and Drug Administration (FDA) (2010). FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Silver Spring, MD: US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/postmarketdrugsafetyInformationforpatientsandproviders/ucm213206.htm#TableofEpidemiologicalStudiesevaluatingfractureriskwithprotonpumpinhibitors (accessed 11 October 2012).
14. Food and Drug Administration (FDA) (2011). FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Silver Spring, MD: US Food and Drug Administration. Available at: http://www.fda.gov/drugs/drugsafety/ucm245011.htm (accessed 30 September 2012).
15. Force R. Meeker A. Cady P. Culbertson V. Force W. Kelley C. (2003) Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 37: 490–493.
16. Gau J. Yang Y. Chen R. Kao T. (2012) Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 21: 553–559.
17. Gilard M. Arnaud B. Cornily J. La Gal G. Lacut K. Le Calvez G. (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) Study. J Am Coll Cardiol 51: 256–260.
18. Gray S. LaCroix A. Larson L. Robbins J. Cauley J. Manson J. (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Int Med 170: 765–771.
19. Graziani G. Badalamenti S. Como G. Gallieni M. Finazzi S. Angelini C. (2002) Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 91: 474–479.
20. Gulmez S. Holm A. Frederiksen H. Jensen T. Pedersen C. Hallas J. (2007) Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Int Med 167: 950–955.
21. Hardy P. Sechet A. Hottelart C. Oprisiu R. Abighanem R. Said S. (1998) Inhibition of gastric acid secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 22: 569–573.
22. Heidelbaugh J. Inadomi J. (2006) Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-intensive care unit hospitalized patients. Am J Gastroenterol 101: 2200–2205.
23. Heidelbaugh J. Goldberg K. Inadomi J. (2009a) Adverse risks associated with proton pump inhibitors: a systematic review. Gastroenterol Hepatol 5: 725–734.
24. Heidelbaugh J. Goldberg K. Inadomi J. (2009b) Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol 104(Suppl. 2): S27–S32.
25. Heidelbaugh J. Goldberg K. Inadomi J. (2010) Magnitude and economic impact of overutilization of antisecretory therapy in the ambulatory care setting. Am J Manag Care 16: e228–e234.
26. Henry E. Carswell A. Wirz A. Fyffe V. McColl K. (2005) Proton pump inhibitors reduce the bioavailability of dietary Vitamin C. Aliment Pharmacol Ther 22: 539–545.
27. Hirschowitz B. Worthington J. Mohnen J. (2008) Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 27: 1110–1121.
28. Hoorn E. van der Hoek J. de Man R. Kuipers E. Bolwerk C. Zietse R. (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56: 112–116.
29. Ho P. Maddox T. Wang L. Fihn S. Jesse R. Peterson E. (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301: 937–944.
30. Howden C. (2000) Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 30: 29–33.
31. Hutchinson C. Geissler C. Powell J. Bomford A. (2007) Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56: 1291–1295.
32. Inadomi J. (2002) On-demand and intermittent therapy for gastro-esophageal reflux disease. Pharmacoeconomics 20: 565–576.
33. Inadomi J. McIntyre L. Bernard L. Fendrick A. (2003) Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 98: 1940–1944.
34. Insogna K. (2009) The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 104(Suppl. 2): S2–S4.
35. Ito T. Jensen R. (2010) Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 12: 448–457.
36. Jayatilaka S. Shakov R. Eddi R. Bakaj G. Baddoura W. DeBari V. (2007) Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 37: 241–247.
37. Kahrilas P. Shaheen N. Vaezi M. (2008) American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 135: 1383–1391.
38. Kaye J. Jick H. (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28: 951–959.
39. Koop H. (1992) Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther 6: 399–406.
40. Laheij R. Sturkenboom M. Hassing R. Dieleman J. Stricker B. Jansen J. (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292: 1955–1960.
41. McColl K. (2009) Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 104(Suppl. 2): S5–S9.
42. Metz D. Inadomi J. Howden C. van Zanten S. Bytzer P. (2007) On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 102: 642–653.
43. Mowat C. Carswell A. Wirz A. McColl K. (1999) Omeprazole and dietary nitrite independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology 116: 813–822.
44. O–Connell M. Madden D. Murray A. Heaney R. Kerzner L. (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118: 778–781.
45. Pham C. Regal R. Bostwick T. Knauf K. (2006) Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 40: 1261–1266.
46. Poulsen A. Christensen S. McLaughlin J. Thomsen R. Sorensen H. Olsen J. (2009) Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 100: 1503–1507.
47. Rozgony N. Fang C. Kuczmarski M. Bob H. (2010) Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder 29: 87–99.
48. Sarkar M. Hennessy S. Yang Y. (2008) Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Int Med 149: 391–398.
49. Sarzynski E. Puttarajappa C. Xie Y. Grover M. Laird-Fick H. (2011) Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 56: 2349–2553.
50. Schenk B. Festen H. Kuipers E. Klinkenberg-Knol E. Meuwissen S. (1996) Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 10: 541–545.
51. Sharma V. Brannon M. Carloss E. (2004) Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 97: 887–889.
52. Sheen E. Triadafilopoulous G. (2011) Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 56: 931–950.
53. Siller-Matula J. Spiel A. Lang I. Kreiner G. Christ G. Jilma B. (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157: 148.e1–148.e5.
54. Small D. Farid N. Payne C. Weerakkody G. Li Y. Brandt J. (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasurgel and clopidogrel. J Clin Pharmacol 48: 475–484.
55. Stewart C. Termanini B. Sutliff V. Serrano J. Yu F. Gibril F. (1998) Iron absorption in patients with Zollinger–Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 12: 83–98.
56. Targownik L. Lix L. Metge C. (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179: 319–326.
57. Targownik L. Lix L. Leung S. Leslie W. (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138: 896–904.
58. Termanini B. Gibril F. Sutliff V. Yu F. Venzon D. Jensen R. (1998) Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger–Ellison syndrome. Am J Med 104: 422–430.
59. University of Michigan Health System (2012) Gastroesophageal reflux disease (GERD). Ann Arbor, MI: University of Michigan Health System. Available at: National Guideline Clearinghouse http://guideline.gov/content.aspx?id=37564&search=gerd (accessed 30 September 2012).
60. Valuck R. Ruscin J. (2004) A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epi 57: 422–428.
61. Vestergaard P. Rejnmark L. Mosekilde L. (2006) Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79: 76–83.
62. Yang Y. Lewis J. Epstein S. Metz D. (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296: 2947–2953.
63. Yearsley K. Gilby L. Ramadas A. Kubiak E. Fone D. Allison M. (2006) Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea. Aliment Pharmacol Ther 24: 613–619.